hapabapa
Bristol-Myers Squibb (NYSE:BMY) will look to continue its streak of beating EPS estimates when it reports Q2 2023 results on July 27 before market open.
The last time the drug giant missed on quarterly EPS was in April 2021 when it reported Q1 2021 results.
The consensus non-GAAP EPS estimate is $1.99 (+3.1% Y/Y) while the consensus revenue estimate is $11.82B (-1% Y/Y).
Over the last two years, Bristol (BMY) has beaten EPS estimates seven out of eight quarters and beaten revenue estimates seven out of eight quarters as well.
Over the last three months, EPS estimates have seen 10 upward revisions and 12 downward. Revenue estimates have seen five upward revisions and 18 downward.
Year to date, shares are down 12%.
Investors will be keen on any pipeline updates and potential growth of the Bristol’s (BMY) top-selling therapies — notably Eliquis (apixaban) and Opdivo (nivolumab) — given the revenue erosion the company has seen since the introduction of generics for its blockbuster Revlimid (lenalidomide) in 2022.
More on Bristol-Myers Squibb
Bristol-Myers Squibb Is A Buy At Current Support (Technical Analysis)
Bristol Myers Squibb: The Gift Has Arrived
The Bristol-Myers Squibb Phenomenon: A Game Changer In The Pharmaceutical Industry
#Bristol #set #continue #streak #EPS #beats #results
